[go: up one dir, main page]

MX2018007390A - Compositions comprising 15-hepe and methods of using the same. - Google Patents

Compositions comprising 15-hepe and methods of using the same.

Info

Publication number
MX2018007390A
MX2018007390A MX2018007390A MX2018007390A MX2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A
Authority
MX
Mexico
Prior art keywords
hepe
compositions
methods
same
relates
Prior art date
Application number
MX2018007390A
Other languages
Spanish (es)
Other versions
MX379262B (en
Inventor
Coughlan David
Climax John
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MX2018007390A publication Critical patent/MX2018007390A/en
Publication of MX379262B publication Critical patent/MX379262B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a las composiciones que comprenden 15-HEPE y a métodos de tratamiento relacionados con las mismas.The present invention relates to compositions comprising 15-HEPE and related treatment methods.

MX2018007390A 2015-12-18 2016-12-19 COMPOSITIONS COMPRISING 15-HYDROXY EICOSAPENTAENOIC ACID (15-HEPE) AND METHODS OF USING SAME. MX379262B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Publications (2)

Publication Number Publication Date
MX2018007390A true MX2018007390A (en) 2018-11-09
MX379262B MX379262B (en) 2025-03-10

Family

ID=57995240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007390A MX379262B (en) 2015-12-18 2016-12-19 COMPOSITIONS COMPRISING 15-HYDROXY EICOSAPENTAENOIC ACID (15-HEPE) AND METHODS OF USING SAME.
MX2021000773A MX394051B (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000773A MX394051B (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Country Status (18)

Country Link
US (5) US9855238B2 (en)
EP (2) EP4218736A3 (en)
JP (4) JP2018537513A (en)
KR (6) KR20220038818A (en)
CN (2) CN108697680A (en)
AR (2) AR107143A1 (en)
AU (4) AU2016370626B2 (en)
BR (1) BR122023026625A2 (en)
CA (2) CA3129008A1 (en)
ES (1) ES2948444T3 (en)
IL (3) IL318963A (en)
MX (2) MX379262B (en)
NZ (1) NZ744323A (en)
PH (1) PH12018501279A1 (en)
RU (2) RU2737089C2 (en)
SG (1) SG11201805149XA (en)
WO (1) WO2017103671A1 (en)
ZA (2) ZA201804779B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
MA41120A (en) 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
EP3294282A1 (en) 2015-05-13 2018-03-21 DS Biopharma Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
CN108025181A (en) 2015-07-21 2018-05-11 艾菲穆恩有限公司 Compositions comprising 15-HEPE for use in the treatment or prevention of cancer and neurological diseases
IL318963A (en) 2015-12-18 2025-04-01 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same
CN113116878A (en) * 2020-01-10 2021-07-16 南京大学 New use of 15S-HEPE for enhancing T cell mediated tumor immunotherapy
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (en) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 Use of 12-HEPE or pharmaceutically acceptable fatty acid thereof to ameliorate spermatogenesis disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (en) * 1992-01-10 1993-07-27 Fujirebio Inc Antiinflammatory agent having immunoregulatory action
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
EP0671901B1 (en) 1993-10-01 1998-01-14 R.P. Scherer Corporation Compositions for dispensing fragrances
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (en) 1998-12-25 2000-07-11 Nof Corp Skin external preparation composition
ATE344226T1 (en) 2000-02-16 2006-11-15 Brigham & Womens Hospital ASPIRIN-RELEASED LIPID MEDIATORS
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CN1268328C (en) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 Coenzyme q and eicosapentaenoic acid (EPA)
EP1564278B1 (en) 2002-11-22 2018-01-10 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
JP2005179211A (en) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd Skin preparation for external use
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (en) * 2005-06-10 2014-05-28 国立大学法人山口大学 Food composition effective in preventing vascular disease
EP2057473B1 (en) 2006-08-08 2014-11-12 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (en) 2008-06-17 2011-12-01 持田製薬株式会社 Non-alcoholic steatohepatitis prevention / improvement / treatment drug
JP2010229099A (en) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd Drugs for improving or treating dyslipidemia
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2972063C (en) * 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2768496A1 (en) 2011-10-19 2014-08-27 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014126356A (en) 2011-11-29 2016-01-27 Дигнити Сайенсиз Лимитед COMPOSITIONS CONTAINING FATTY ACIDS WITH A CHAIN OF 20 CARBON ATOMS, AND METHODS FOR PRODUCING AND USING THEM
PT2800563T (en) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
CA2867168A1 (en) * 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
ES2606392T3 (en) 2012-04-04 2017-03-23 Pronova Biopharma Norge As Compositions comprising omega-3 and vitamin D fatty acids for acne vulgaris and / or eczema, and procedures and uses thereof
US10568858B2 (en) * 2012-05-10 2020-02-25 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105530927A (en) * 2013-07-18 2016-04-27 持田制药株式会社 Self-emulsifying compositions of omega-3 fatty acids
EP3878835A1 (en) * 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
KR20160132372A (en) * 2014-01-10 2016-11-18 디그너티 사이언스 리미티드 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (en) * 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
CN113893240A (en) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 Compositions comprising 15-HEPE and methods of use thereof
EP3294282A1 (en) * 2015-05-13 2018-03-21 DS Biopharma Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
CN108025181A (en) * 2015-07-21 2018-05-11 艾菲穆恩有限公司 Compositions comprising 15-HEPE for use in the treatment or prevention of cancer and neurological diseases
IL318963A (en) 2015-12-18 2025-04-01 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same

Also Published As

Publication number Publication date
IL318963A (en) 2025-04-01
PH12018501279A1 (en) 2019-01-28
AU2020267224A1 (en) 2020-12-10
US20170172965A1 (en) 2017-06-22
RU2018126361A (en) 2020-01-22
NZ766360A (en) 2025-05-30
CN108697680A (en) 2018-10-23
CA3129008A1 (en) 2017-06-22
BR112018012313A2 (en) 2018-12-04
RU2737089C2 (en) 2020-11-24
AU2016370626B2 (en) 2020-08-20
EP3389647A1 (en) 2018-10-24
JP2023153863A (en) 2023-10-18
AU2020267224B2 (en) 2022-09-29
RU2018126361A3 (en) 2020-01-22
KR20230047501A (en) 2023-04-07
KR20180094516A (en) 2018-08-23
RU2020137883A (en) 2020-12-03
ZA202104969B (en) 2023-01-25
MX379262B (en) 2025-03-10
SG11201805149XA (en) 2018-07-30
US20180104207A1 (en) 2018-04-19
CA3008774A1 (en) 2017-06-22
KR20240052856A (en) 2024-04-23
WO2017103671A1 (en) 2017-06-22
NZ783466A (en) 2025-05-30
EP3389647B1 (en) 2023-04-05
IL259846A (en) 2018-07-31
NZ744323A (en) 2020-08-28
US9855238B2 (en) 2018-01-02
JP2020063259A (en) 2020-04-23
EP4218736A2 (en) 2023-08-02
CA3008774C (en) 2021-10-12
AU2022291628B2 (en) 2025-04-03
AR107143A1 (en) 2018-03-28
AR134220A2 (en) 2025-12-10
AU2022291628A1 (en) 2023-02-02
JP2021178840A (en) 2021-11-18
KR20250130433A (en) 2025-09-01
US20190224154A1 (en) 2019-07-25
AU2025201593A1 (en) 2025-03-20
US12274685B2 (en) 2025-04-15
US20230106655A1 (en) 2023-04-06
MX394051B (en) 2025-03-24
ZA201804779B (en) 2019-09-25
JP2018537513A (en) 2018-12-20
MX2021000773A (en) 2022-07-19
AU2016370626A1 (en) 2018-08-02
ES2948444T3 (en) 2023-09-12
KR20220038818A (en) 2022-03-29
KR20200055154A (en) 2020-05-20
IL294736A (en) 2022-09-01
CN113230244A (en) 2021-08-10
EP4218736A3 (en) 2023-10-18
US20250281442A1 (en) 2025-09-11
BR122023026625A2 (en) 2024-01-16
US10231945B2 (en) 2019-03-19

Similar Documents

Publication Publication Date Title
MX2018007390A (en) Compositions comprising 15-hepe and methods of using the same.
CL2019000609A1 (en) Variants of acid alpha-glucosidase and uses thereof.
ECSP17029371A (en) ROR-GAMMA INHIBITING DIHYDROPYRROLOPYRIDINES
EP3394698C0 (en) COMPUTER-AID LOCALIZATION OF FIBRILLATION SOURCES
MX373103B (en) CYCLOPROPYLAMINES AS INHIBITORS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1).
EP3388004A4 (en) TREATMENT INSTRUMENT
EP3509581A4 (en) FORMULATIONS OF (R
MX375352B (en) NRF2 REGULATORS.
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF IL-6-ASSOCIATED DISEASES
CL2019000610A1 (en) Variants of acid alpha-glucosidase and uses thereof.
PL3277270T3 (en) COMPOSITIONS AND METHODS OF TREATMENT OF ISKNIA
BR112017005266A2 (en) mk2 inhibitors and their use
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX389447B (en) COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6.
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
PT3645518T (en) SUMMARY OF OMECAMTIV MECARBIL
EP3360010A4 (en) ACCORDABLE SOURCE OF BI-PHOTONS
MX2016009590A (en) APILIMOD COMPOSITIONS AND METHODS TO USE THE SAME.
PT3223827T (en) COMPOSITION OF DIETARY FIBERS
BR112018002382A8 (en) NEW HUMAN ANTI-GVPI ANTIBODIES AND THEIR USES
BR112017016562A2 (en) production methods of liquid compositions
MX2016012784A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions.
EP3283115C0 (en) COMPOSITIONS FOR THE TREATMENT OF AUTISM
PL3373922T3 (en) COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF HOMOCYSTINURY
EP3513304A4 (en) PROVISION OF RECOMMENDED CONTENT